Your browser doesn't support javascript.
loading
Roles of omalizumab in various allergic diseases.
Okayama, Yoshimichi; Matsumoto, Hisako; Odajima, Hiroshi; Takahagi, Shunsuke; Hide, Michihiro; Okubo, Kimihiro.
Afiliação
  • Okayama Y; Allergy and Immunology Research Project Team, Research Institute of Medical Science, Nihon University School of Medicine, Tokyo, Japan; Center for Allergy, Nihon University Itabashi Hospital, Tokyo, Japan; Center for Medical Education, Nihon University School of Medicine, Tokyo, Japan. Electronic ad
  • Matsumoto H; Department of Respiratory Medicine, Graduate School of Medicine Kyoto University, Kyoto, Japan. Electronic address: hmatsumo@kuhp.kyoto-u.ac.jp.
  • Odajima H; Department of Pediatrics, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan. Electronic address: odajima.hiroshi.uk@mail.hosp.go.jp.
  • Takahagi S; Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Hide M; Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Electronic address: ed1h-w1de-road@hiroshima-u.ac.jp.
  • Okubo K; Department of Otorhinolaryngology, Nippon Medical School, Tokyo, Japan. Electronic address: ent-kimi@nms.ac.jp.
Allergol Int ; 69(2): 167-177, 2020 Apr.
Article em En | MEDLINE | ID: mdl-32067933
ABSTRACT
IgE and mast cells play a pivotal role in various allergic diseases, including asthma, allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody, has significantly improved control of these allergic diseases and introduced a new era for the management of severe allergic conditions. About 10 years of experience with omalizumab treatment for severe allergic asthma confirmed its effectiveness and safety, reducing symptoms, frequency of reliever use, and severe exacerbations in patients with intractable conditions. Omalizumab is particularly useful in childhood asthma, where atopic conditions often determine clinical courses of asthma. Recently, omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) with the fixed dose of 300 mg. Although the mechanisms underlying the actions of omalizumab in CSU are not fully clarified, nearly 90% of patients with CSU showed a complete or a partial response to omalizumab treatment. Furthermore, omalizumab is just approved for the treatment of severe Japanese cedar pollinosis (JC) based on the successful results of an add-on study of omalizumab for inadequately controlled severe pollinosis despite antihistamines and nasal corticosteroids. For proper use of omalizumab to treat severe JC, co-administration of antihistamines is necessary, while patients should meet the criteria including strong sensitization to Japanese cedar pollen (≥class 3) and poor control under standard treatment. In the management of severe allergic diseases using omalizumab, issues including cost and concerns about relapse after its discontinuation should be overcome. At the same time, possibilities for application to other intractable allergic diseases should be considered.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulina E / Antialérgicos / Omalizumab / Hipersensibilidade / Anticorpos Monoclonais Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulina E / Antialérgicos / Omalizumab / Hipersensibilidade / Anticorpos Monoclonais Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article